<p><strong>Corcept Therapeutics Inc. </strong>(NASDAQ:CORT) shares are up on Friday as the company reported significant findings from its Phase 2 DAZALS study, demonstrating an 87% reduction in the risk of death for patients with amyotrophic lateral sclerosis (ALS) compared to those receiving a placebo.</p>



<h2>Corcept DAZALS Phase 2 Data Drives CORT Stock Move</h2>



<p>The DAZALS study revealed that patients treated with 300 mg of dazucorilant daily exhibited improved overall survival rates.</p>



<p>ALS, or Lou Gehrig’s disease, is a progressive, fatal neurodegenerative disease that destroys motor neurons in the brain and spinal cord, causing voluntary muscle loss, paralysis, and respiratory failure.</p>



<div>


<p>
<strong>
Read Also:

What's Behind The Jump In Corcept Therapeutics Stock?
</strong>
</p>


</div>


<h2>Survival Benefit Observed Despite Missed Primary Endpoint</h2>



<p>The commercial-stage pharmaceutical company said that although DAZALS did not meet its primary endpoint, at the end of the 24-week treatment period, patients who received 300 mg of dazucorilant daily did exhibit improved overall survival.</p>



<p>The finding is consistent with the 84% reduction in risk of death observed after one year of treatment.</p>



<p>Similar survival benefit was observed at both the one-year and two-year marks in patients who received 300 mg of dazucorilant for more than 24 weeks, whether in the treatment period or in the long-term extension phase, compared to patients who received either placebo or 150 mg of dazucorilant for more than 24 weeks and did not receive dazucorilant in the extension phase.</p>



<p>Between these groups, the reduction in risk of death in patients who received 300 mg of dazucorilant was 64% at one year and 61% at two years.</p>



<h2>Earnings Miss And Revenue Shortfall</h2>



<p>Corcept Therapeutics reported a loss of 30 cents per share, missing the consensus loss of 16 cents.</p>



<p>Sales reached $164.9 million, missing the consensus of $192.51 million.</p>



<p>The company on Thursday raised its fiscal 2026 sales guidance from $900 million-$1 billion to $950 million-$1.05 billion compared to the consensus of $941.18 million.</p>



<h2>How CORT Ranks On Value, Quality And Momentum</h2>



<p>Below is the Benzinga Edge scorecard for Corcept Therapeutics, highlighting its strengths and weaknesses compared to the broader market:</p>



<ul>
<li><strong>Value</strong>: Weak (Score: 19.85) — Trading at a steep premium relative to peers.</li>



<li><strong>Quality</strong>: Strong (Score: 80.22) — Balance sheet remains healthy.</li>



<li><strong>Momentum</strong>: Weak (Score: 7.93) — Stock is underperforming the broader market.</li>
</ul>



<p><strong>The Verdict:</strong> Corcept Therapeutics’s Benzinga Edge signal reveals a mixed profile, with strong quality metrics but weak momentum and value scores. This suggests the stock may face challenges in sustaining upward movement without broader market support.</p>



<p><strong>CORT Price Action:</strong> Corcept Therapeutics shares were up 3.37% at $48.09 at the time of publication on Friday, according to Benzinga Pro data.</p>



<p><em>Photo: Billion Photos / Shutterstock</em></p>



<div>


<p><strong>
Read Also:

Colgate Sees Middle East Conflict Pressuring Costs And Consumer Spending Worldwide
</strong></p>


</div>

CORT

ARKG

<p>Corcept Therapeutics shares rose after the Phase 2 DAZALS study showed an 87% reduction in death risk for ALS patients treated with 300 mg of dazucorilant daily. Despite missing its primary endpoint, the study indicated improved survival rates. The company reported a loss of 30 cents per share and revenue of $164.9 million, both below expectations, but raised its 2026 sales outlook to $950 million-$1.05 billion. The stock is currently up 3.37% at $48.09, reflecting mixed performance metrics in value, quality, and momentum.</p>

Corcept Therapeutics Pivotal Study Shows 87% Lower Death Risk